Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) on Chemotherapy-Induced Myelosuppression in Patients with Chronic Lymphocytic Leukemia: A Crossover Study

References

• American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony‐stimulating factors: evidence‐based, clinical practice guidelines. J. Clin. Oncol. 1994; 12: 2471–2508
   PubMed Web of Science ®Google Scholar
• Harmenberg J., Höglund M., Hellström‐Lindberg E. G‐ and GM‐CSF in oncology and oncological haematology. Eur. J. Haematol 1994; 52: 1–28
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O. Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 1995; 13: 1023–1035
   PubMed Web of Science ®Google Scholar
• Itälä M., Remes K. The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukemia. Leuk. Lymphoma 1996, in press
   PubMed Web of Science ®Google Scholar
• Cytel Software Corporation. StatXact, statistical software for exact nonparametric inference. User manual version 2. Cytel Software Corporation, Cambridge, MAUSA 1991
   Google Scholar
• Liepman M., Votaw M. L. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978; 41: 1664–1669
   PubMed Web of Science ®Google Scholar
• Oken M. M., Kaplan E. K. Combination chemotherapy with cyclophosphamide, vincristine, and pred‐nisone in the treatment of refractory chronic lymphocytic leukemia. Cancer. Treatm. Rep. 1979; 63: 441–447
   PubMedGoogle Scholar
• Montserrat E., Alcala A., Parody R., et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369–2375
   PubMed Web of Science ®Google Scholar
• Biesma B., de Vries E. G. E., Willemse P. H. B., et al. Efficacy and tolerability of recombinant human granulocyte‐macrophage colony‐stimulating factor in patients with chemotherapy‐related leukopenia and fever. Eur. J. Cancer 1990; 26: 932–936
   PubMed Web of Science ®Google Scholar
• Kaplan L. D., Kahn J. O., Crowe S., et al. Clinical and virologic effects of recombinant human granulocyte‐macrophage colony‐stimulating factor in patients receiving chemotherapy for human immunodeficiency virus‐associated non‐Hodgkin's lymphoma: results of a randomised trial. J. Clin. Oncol 1991; 9: 929–940
   PubMed Web of Science ®Google Scholar
• de Vries E. G. E., Biesma B., Willemse P. H. B., et al. A double‐blind placebo‐controlled study with granu‐locyte‐macrophage colony‐stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res. 1991; 51: 116–122
   PubMed Web of Science ®Google Scholar
• Gerhartz H. H., Engelhard M., Meusers P., et al. Randomized, double‐blind, placebo‐controlled, phase III study of recombinant human granulocyte‐macrophage colony‐stimulating factor as adjunct to induction treatment of high‐grade malignant non‐Hodgkin's lymphomas. Blood 1993; 82: 2329–2339
   PubMed Web of Science ®Google Scholar
• Hamm J. T., Schiller J. H., Oken M. M., et al. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) in small cell carcinoma of the lung (SCCL): preliminary analysis of a randomized controlled trial. Proc. Am. Soc. Clin. Oncol. 1991; 10: 255, abstr
   Google Scholar
• Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte colony‐stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 1990; 323: 871–877
   PubMed Web of Science ®Google Scholar
• Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony‐stimulating factor of fever and neutrope‐nia induced by chemotherapy in patients with small‐cell lung cancer. N. Engl. J. Med. 1991; 325: 164–170
   PubMed Web of Science ®Google Scholar
• Pettengell R., Gurney G., Radford J., et al. Granulocyte colony‐stimulating factor to prevent dose‐limiting neutropenia in non‐Hodgkins lymphoma: a randomised controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Trillet‐Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer 1993; 29A: 319–324
   PubMed Web of Science ®Google Scholar
• Nichols C., Bajorin D., Schmoll H. J., et al. VIP chemotherapy with/without GM‐CSF for poor risk, relapsed, or refractory germ cell tumors (GCT): preliminary analysis of a randomized controlled trial. Proc. Am. Soc. Clin. Oncol. 1991; 10: 167, abstr
   Google Scholar
• Bunn P. A., Jr., Crowley J., Kelly K., et al. Chemoradiotherapy with or without granulocyte‐macrophage colony‐stimulating factor in the treatment of limited‐stage small‐cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J. Clin. Oncol. 1995; 13: 1632–1641
   PubMed Web of Science ®Google Scholar
• Amman K. S., Griffin J. D., Elias A., et al. Effect of recombinant human granulocyte‐macrophage colony‐stimulating factor on chemotherapy‐induced myelosuppression. N. Engl. J. Med. 1988; 319: 593–598
   PubMed Web of Science ®Google Scholar
• Herrmann F., Schulz G., Wieser M., et al. Effect of granulocyte‐macrophage colony‐stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am. J. Med 1990; 88: 619–624
   PubMed Web of Science ®Google Scholar
• Mughal T. I., O'Neill K. A phase II study of recombinant granulocyte macrophage colony stimulating factor in patients with non‐Hodgkin's lymphoma. Leuk. Lymphoma 1994; 14: 331–334
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Talpaz M., Gomez J. A., et al. Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐over high‐dose administration in selected patients. Br. J. Haematol. 1991; 78: 352–358
   PubMed Web of Science ®Google Scholar
• Morstyn G. The impact of colony stimulating factors on cancer chemotherapy. Br. J. Haematol. 1990; 75: 303–307
   PubMed Web of Science ®Google Scholar
• Cebon J., Lieschke G. J., Bury R. W., Morstyn G. The dissociation of GM‐CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br. J. Haematol. 1992; 80: 144–150
   PubMed Web of Science ®Google Scholar
• Barlogie B., Jagannath S., Dixon D. O., et al. High‐dose melphalan and granulocyte‐macrophage colony‐stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677–680
   PubMed Web of Science ®Google Scholar
• Edmonson J. H., Long H. J., Kvols L. K. Cytotoxic drugs plus subcutaneous granulocyte‐macrophage colony‐stimulating factor: can molgramostim enhance antisarcoma therapy?. J. Natl. Cancer. Inst. 1994; 86: 312–314
   PubMed Web of Science ®Google Scholar
• Ragnhammar P., Fagerberg J., Frodin J. E., et al. Effect of monoclonal antibody 17‐IA and GM‐CSF in patients with advanced colorectal carcimona—long‐lasting, complete remissions can be induced. Int. J. Cancer 1993; 53: 751–758
   PubMed Web of Science ®Google Scholar
• Itala M., Pelliniemi T. ‐T., Remes K., Vainio O. Effects of long‐term treatment with GM‐CSF on blood cell counts, lymphocyte subsets, and granulocyte functions in patients with chronic lymphocytic leukemia, Submitted for publication
   Google Scholar